Addison’s Disease Market Research Report by Diagnosis (Laboratory Testing and Imaging Tests), Treatment (Oral Corticosteroid and Corticosteroid Injections), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others)-Forecast till 2032

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Addison’s Disease Market, by Diagnosis

6.1 Introduction

6.2 Laboratory Testing

6.2.1 Blood Tests

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.2 ACTH Stimulation Test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.3 Insulin-Induced Hypoglycemia test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.4 Other Tests

6.3 Imaging Tests

6.3.1 Chest Radiography

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.2 CT Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Addison’s Disease Market, by Treatment

7.1 Introduction

7.2 Oral Corticosteroids

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Corticosteroid Injections

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Addison’s Disease Market, by End User

8.1 Introduction

8.2 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Diagnostic Laboratories

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Other End Users

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Addison’s Disease Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Pfizer Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Boehringer Ingelheim International GmbH

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Shire

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Tocris Bioscience

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 GlaxoSmithKline plc

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Merck KGaA

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Lupin Pharmaceuticals, Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Abbott

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Amgen Limited & Amgen Ireland Limited

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Bayer AG

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Biogen

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Eli Lilly and Company

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Novartis AG

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Diurnal

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Switzer Life science Pvt. Ltd.

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Addison’s Disease Industry

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Addison’s Disease Market Synopsis, 2020–2027

Table 2 Global Addison’s Disease Market Estimates and Forecast, 2020–2027

(USD Million)

Table 3 Global Addison’s Disease Market, by Region, 2020–2027 (USD Million)

Table 4 Global Addison’s Disease Market, by Diagnosis, 2020–2027 (USD Million)

Table 5 Global Addison’s Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 6 Global Addison’s Disease Market, by End User, 2020–2027 (USD

Million)

Table 7 North America: Addison’s Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 8 North America: Addison’s Disease Market, by Treatment, 2020–2027

(USD Million)

Table 9 North America: Addison’s Disease Market, by End User, 2020–2027

(USD Million)

Table 10 US: Addison’s Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 11 US: Addison’s Disease Market, by Treatment, 2020–2027

(USD Million)

Table 12 US: Addison’s Disease Market, by End User, 2020–2027 (USD Million)

Table 13 Canada: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD

Million)

Table 14 Canada: Addison’s Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 15 Canada: Addison’s Disease Market, by End User, 2020–2027 (USD

Million)

Table 16 South America: Addison’s Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 17 South America: Addison’s Disease Market, by Treatment, 2020–2027

(USD Million)

Table 18 South America: Addison’s Disease Market, by End User, 2020–2027

(USD Million)

Table 19 Europe: Addison’s Disease Market, by Diagnosis, 2020–2027 (USD

Million)

Table 20 Europe: Addison’s Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 21 Europe: Addison’s Disease Market, by End User, 2020–2027 (USD

Million)

Table 22 Western Europe: Addison’s Disease Market, by Diagnosis, 2020–

2027 (USD Million)

Table 23 Western Europe: Addison’s Disease Market, by Treatment, 2020–

2027 (USD Million)

Table 24 Western Europe: Addison’s Disease Market, by End User, 2020–2027

(USD Million)

Table 25 Eastern Europe: Addison’s Disease Market, by Diagnosis, 2020–

2027 (USD Million)

Table 26 Eastern Europe: Addison’s Disease Market, by Treatment, 2020–2027

(USD Million)

Table 27 Eastern Europe: Addison’s Disease Market, by End User, 2020–2027

(USD Million)

Table 28 Asia-Pacific: Addison’s Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 29 Asia-Pacific: Addison’s Disease Market, by Treatment, 2020–2027

(USD Million)

Table 30 Asia-Pacific: Addison’s Disease Market, by End User, 2020–2027 (USD

Million)

Table 31 Middle East & Africa: Addison’s Disease Market, by Diagnosis,

2020–2027 (USD Million)

Table 32 Middle East & Africa: Addison’s Disease Market, by Treatment, 2020–

2027 (USD Million)

Table 33 Middle East & Africa: Addison’s Disease Market, by End User, 2020–

2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Addison’s Disease Market

Figure 3 Segmentation Market Dynamics for Global Addison’s Disease Market

Figure 4 Global Addison’s Disease Market Share, by Diagnosis, 2020

Figure 5 Global Addison’s Disease Market Share, by Treatment, 2020

Figure 6 Global Addison’s Disease Market Share, by End User, 2020

Figure 7 Global Addison’s Disease Market Share, by Region, 2020

Figure 8 North America: Addison’s Disease Market Share, by Country, 2020

Figure 9 Europe: Addison’s Disease Market Share, by Country, 2020

Figure 10 Asia-Pacific: Addison’s Disease Market Share, by Country, 2020

Figure 11 Middle East & Africa: Addison’s Disease Market Share, by Country, 201

Figure 12 Global Addison’s Disease Market: Company Share Analysis, 2020 (%)

Figure 13 Pfizer Inc.: Key Financials

Figure 14 Pfizer Inc.: Segmental Revenue

Figure 15 Pfizer Inc.: Geographical Revenue

Figure 16 Boehringer Ingelheim International GmbH: Key Financials

Figure 17 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 18 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 19 Shire: Key Financials

Figure 20 Shire: Segmental Revenue

Figure 21 Shire: Geographical Revenue

Figure 22 Tocris Bioscience: Key Financials

Figure 23 Tocris Bioscience: Segmental Revenue

Figure 24 Tocris Bioscience: Geographical Revenue

Figure 25 GlaxoSmithKline Plc: Key Financials

Figure 26 GlaxoSmithKline Plc: Segmental Revenue

Figure 27 GlaxoSmithKline Plc. Geographical Revenue

Figure 28 Merck KGaA : Key Financials

Figure 29 Merck KGaA : Segmental Revenue

Figure 30 Merck KGaA : Geographical Revenue

Figure 31 Lupin Pharmaceuticals, Inc.: Key Financials

Figure 32 Lupin Pharmaceuticals, Inc.: Segmental Revenue

Figure 33 Lupin Pharmaceuticals, Inc.: Geographical Revenue

Figure 34 Abbott: Key Financials

Figure 35 Abbott: Segmental Revenue

Figure 36 Abbott: Geographical Revenue

Figure 37 Amgen Limited & Amgen Ireland Limited: Key Financials

Figure 38 Amgen Limited & Amgen Ireland Limited: Segmental Revenue

Figure 39 Amgen Limited & Amgen Ireland Limited: Geographical Revenue

Figure 40 Bayer AG: Key Financials

Figure 41 Bayer AG: Segmental Revenue

Figure 42 Bayer AG: Geographical Revenue

Figure 43 Biogen: Key Financials

Figure 44 Biogen: Segmental Revenue

Figure 45 Biogen: Geographical Revenue

Figure 46 Eli Lilly and Company: Key Financials

Figure 47 Eli Lilly and Company: Segmental Revenue

Figure 48 Eli Lilly and Company: Geographical Revenue

Figure 49 Novartis AG: Key Financials

Figure 50 Novartis AG: Segmental Revenue

Figure 51 Novartis AG: Geographical Revenue

Figure 52 Diurnal: Key Financials

Figure 53 Diurnal: Segmental Revenue

Figure 54 Diurnal: Geographical Revenue

Figure 55 Switzer Life science Pvt. Ltd.: Key Financials

Figure 56 Switzer Life science Pvt. Ltd.: Segmental Revenue

Figure 57 Switzer Life science Pvt. Ltd.: Geographical Revenue